Could muscle relaxants be life-saving in acute respiratory distress syndrome (ARDS)? The ACURASYS trial unveils how cisatracurium, used early in severe ARDS, improved survival, reshaping ventilatory management strategies. The ACURASYS trial investigated the effects of early administration of a 48-h infusion of cisatracurium, a neuromuscular blocking agent, in patients with severe ARDS. This randomized controlled trial included 340 patients with a PaO2/FiO2 ratio of less than 150. The cisatracurium group showed significantly lower 90-day mortality (31.6% vs. 40.7%) compared to the placebo group, despite similar rates of adverse events, including ICU-acquired weakness. The study highlighted the role of early neuromuscular blockade in improving oxygenation and outcomes when combined with lung-protective ventilation strategies.